Related Experiment Video
Updated: Jul 16, 2026

A Neonatal Imaging Model of Gram-Negative Bacterial Sepsis
Published on: August 12, 2020
Low serum levels of mannose binding lectin are a risk factor for neonatal sepsis
Fabrizio de Benedetti1, Cinzia Auriti, Leila E D'Urbano
1Scientific Direction, Bambino Gesù Children's Hospital-IRCCS, 00165 Rome, Italy. debenedetti@opbg.net
Abstract:
Mannose binding lectin (MBL) is a soluble pattern recognition receptor of innate immunity that binds a wide range of pathogens and exerts opsonic effects. We investigated the association between serum MBL levels and development of sepsis in infants admitted to neonatal intensive care units (NICUs). Serum MBL levels on admission were measured by enzyme-linked immunosorbent assay (ELISA) in 206 neonates consecutively admitted to an NICU of whom 138 did not develop hospital-acquired sepsis and 68 did. Of these 68, 40 had confirmed sepsis with positive blood cultures, 19 clinically suspected sepsis, with negative blood cultures, and nine had clinically suspected sepsis with blood culture yielding coagulase-negative staphylococci (CoNS). Serum MBL levels on admission were significantly lower in infants with sepsis [0.45 microg/mL; interquartile range (IQR) 0.09-1.68], particularly in those with confirmed sepsis (0.17 microg/mL; IQR 0.05-0.96), compared with infants without sepsis (1.45 microg/mL; IQR 0.43-3.52), and infants with CoNS-positive blood culture (1.70 microg/mL: IQR 0.85-3.60). After adjusting for duration of exposure gestational age (GA) and birth weight (BW), the association of low MBL levels with development of sepsis was maintained [odds ratio (OR) = 0.52; 95% confidence interval (CI): 0.36-0.75]. The measurement of serum MBL levels on admission in NICU may help to identify neonates at higher risk of developing sepsis.
Insights
Low serum mannose-binding lectin (MBL) levels in neonates admitted to the NICU are associated with an increased risk of developing sepsis. Measuring MBL may help identify high-risk infants for early intervention.
Area of Science:
- Immunology
- Neonatal Medicine
- Infectious Diseases
Background:
- Mannose-binding lectin (MBL) is a key component of innate immunity, recognizing and binding pathogens.
- MBL plays a crucial role in the early defense against infections, particularly in vulnerable populations like neonates.
- Low MBL levels have been hypothesized to increase susceptibility to infections.
Purpose of the Study:
- To investigate the association between serum mannose-binding lectin (MBL) levels and the development of sepsis in infants admitted to neonatal intensive care units (NICUs).
- To determine if MBL levels can serve as a predictive biomarker for sepsis in neonates.
Main Methods:
- Serum MBL levels were measured using ELISA in 206 neonates admitted to an NICU.
- Infants were categorized into groups with and without sepsis, including confirmed sepsis, clinically suspected sepsis, and sepsis with coagulase-negative staphylococci (CoNS) positive blood cultures.
- Statistical analysis, including adjustment for gestational age and birth weight, was performed to assess the association between MBL levels and sepsis development.
Main Results:
- Serum MBL levels on admission were significantly lower in infants who developed sepsis compared to those who did not.
- Infants with confirmed sepsis or CoNS-positive blood cultures exhibited particularly low MBL levels.
- Low MBL levels remained a significant predictor of sepsis development after adjusting for gestational age and birth weight (OR = 0.52; 95% CI: 0.36-0.75).
Conclusions:
- Serum MBL levels on admission are a potential biomarker for identifying neonates at higher risk of developing sepsis in the NICU.
- Early measurement of MBL may facilitate timely interventions and improve outcomes for at-risk infants.
- Further research could explore therapeutic strategies targeting MBL to prevent or treat neonatal sepsis.
Related Concept Videos
Bacterial Meningitis
Bacterial Meningitis II: Pathophysiology
Bacterial Meningitis I: Introduction
